Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.77 |
| ▸ | CDK4 | P11802 | 14/20 | 0.77 |
| ▸ | AURKA | O14965 | 8/20 | 0.77 |
| ▸ | CDK9 | P50750 | 7/20 | 0.77 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.77 |
| ▸ | CDK1 | P06493 | 6/20 | 0.77 |
| ▸ | CDK7 | P50613 | 6/20 | 0.77 |
| ▸ | PLK1 | P53350 | 2/20 | 0.67 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27684377 | 0.90 | CDK2 (0.64) | CDK2CDK4AURKACDK9AURKB | |
| SCHEMBL4162643 | 0.90 | CDK2 (0.74) | CDK2CDK4AURKACDK9AURKB | |
| SCHEMBL4158705 | 0.89 | CDK2 (0.82) | CDK2CDK4AURKACDK9AURKB | |
| SCHEMBL2075981 | 0.88 | CDK2 (0.66) | CDK2CDK4AURKACDK9AURKB | |
| SCHEMBL4162962 | 0.87 | CDK2 (1.00) | CDK2CDK4AURKACDK9AURKB | |
| SCHEMBL2076580 | 0.85 | CDK2 (0.74) | CDK2CDK4AURKACDK9AURKB | |
| SCHEMBL4165538 | 0.84 | CDK4 (0.69) | CDK2CDK4AURKACDK9AURKB | |
| SCHEMBL2086230 | 0.82 | CDK2 (0.65) | CDK2CDK4AURKACDK9AURKB | |
| SCHEMBL4161731 | 0.82 | CDK2 (0.69) | CDK2CDK4AURKACDK9AURKB | |
| SCHEMBL1808809 | 0.82 | CDK2 (0.72) | CDK2CDK4AURKACDK9AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | claimed |
| EP-1756098-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2007-02-28 | — | — | EP | claimed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | claimed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| EP-1756098-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CDK2, CDK4, CDK20 | CDK2 1/4885CDK4 2/4885AURKA 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.